Sarep­ta halts Duchenne gene ther­a­py in some pa­tients af­ter sec­ond death

Sarep­ta Ther­a­peu­tics re­port­ed a sec­ond pa­tient death due to liv­er fail­ure re­lat­ed to its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py Ele­v­idys, and said it’s sus­pend­ing ship­ments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER